AcousticaBio Analysis: $3M Raised
What is AcousticaBio?
AcousticaBio uses a Harvard-patented acoustophoretic platform to convert intravenous biologics into ultra-high concentration subcutaneous injections. The technology achieves concentrations exceeding 500 mg/mL without solvents or post-processing. The company collaborates with biopharma partners to enable patients to self-administer life-saving medications at home.
Location
Cambridge, United States
Employees
11-50
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- Acoustophoretic platform for ultra-high concentration biologics
- Microgel suspension formulations
- Subcutaneous injection formulations for monoclonal antibodies, ADCs, bispecifics, and fusion proteins
Use Cases
Convert IV monoclonal antibodies to subcutaneous injections for home self-administration; Formulate antibody-drug conjugates for improved patient access; Enable patients to self-administer fusion proteins and bispecifics; Reduce hospital visits for chronic therapy patients; Improve stability and reduce aggregation in high-concentration biologics
Other Considerations
Selected as a spoke of ARPA-H Investor Catalyst Hub (October 2024); Focuses on high-concentration biologics beyond 500 mg/mL; Patented acoustophoretic technology from Harvard
See something that needs updating? Suggest edits to this profile.